Immunogen To Test Drug. Immunogen Inc. today confirmed an investment bank's report that the company planned to begin human clinical trials of its major drug, Oncolysin B, for treating lymphoma and
10/14/2021. ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its third quarter operating results.